Our promise to society
Dear associates, patients and partners
At Ipsen we take our Corporate Social Responsibility seriously – and that is why we prefer to call it our ‘Company Social Responsibility’ because these commitments underpin everything we do. Our Company Social Responsibility involves working & engaging around the highest ethical standards in everything we do. We strive to instil understanding of our values and to empower people to make decisions in light of these values, and in the best interest of patients. We are committed to continue to build bridges for patient care, which means:
Listening to patients so we can truly understand their needs and the many challenges they face as we accompany them throughout their life.
Doing our very best to ensure that patients have access to the treatments they require as quick as possible because patients can’t wait!
Adhering the highest ethical standards to ensure that our decisions are made in the best interests of patients.
To achieve this, we believe that our employees are our ambassadors who can truly make a difference. Through the values of our organization we attract ambitious people who are drawn by a purpose to have a direct impact on people’s lives through their work. By recruiting the right people we aim to be an employer of choice in the biotech/pharmaceutical industry, offering employees a wealth of challenges and opportunities, whose end goal is a better life for our patients.
Along with our dedication to improving people’s lives, we are also firmly committed to protecting the environment and to supporting civil society and the communities in which we operate. We are committed to caring for our people and the planet by integrating design for the environment and safety principles into all aspects of our business; from the research and development of our products, through our supply chain and manufacturing operations and ultimately to our customers.
We show our commitment to innovation for patient care by working with all our stakeholders including patient advocacy groups, nurses, carers, physicians, regulatory authorities and policy makers on a global and local level to better understand today’s healthcare challenges, societal needs and the patient journey. This information can help inform the design of our programs to support disease awareness and patient empowerment.
Our activities worldwide require a large Ipsen investment in the community, with efforts focusing on patient associations and charitable work. We are delighted to be involved in so many initiatives that enable us to support the fantastic work of so many partner organizations, who have the same goal as us – to make the lives of our patients better for longer.
As we look forward we will continue to seek new opportunities to work with all our partners, at every stage of the drug life cycle, in creating sustainable value for patients, healthcare systems and society. Ipsen is already a growth story. But with focus on our key strengths – our portfolio, our pipeline, our partnerships and our people – we can look forward to further innovative and sustainable growth in the years to come.
In conclusion, promoting the needs and rights of patients, employees and society at large is really important, and it is exactly the objective and essence of our Company Social Responsibility strategy: a human journey of shared commitments. Our vison is to harness the power of our employees to have a responsible and sustainable impact on patients, Society and the environment.
Chief Executive Officer, Ipsen
Ethics & compliance
Ethics & compliance
Our bold and entrepreneurial spirit combined with the highest ethical standards constitutes the heart of our organisation. This is the foundation of our approach to listen, partner and work with all of our stakeholders.
Our dedication to improve the health and quality of life of our patients demands the uppermost ethical standards throughout all areas of company life, from research and development through to marketing. We ensure that all decisions are made independently, in the best interests of patients and in compliance with all applicable laws, regulations, industry codes, Ipsen policies and the Ipsen Code of Conduct. We strive to instil understanding of our values & to empower people to make decisions in light of these values, and in the best interest of patients.
Ethics & compliance
Promoting a culture of ethics and compliance across the organization is a key objective for us, reflected in our global Ethics and Compliance program, with the Ipsen Code of Conduct as the cornerstone. It is set out to achieve two main objectives: to integrate essential ethical concepts across Ipsen and, more specifically, to mobilize Ipsen’s teams around our vision.
The code sets out the six pillars of Ethics at Ipsen:
Healthcare and patient focus
Everything we do is intended to benefit patients’ health
We are committed to quality, compliance, ethics and integrity in everything we do
We respect the need for independent and autonomous decision-making by all parties
We commit that everything we do is aligned with Ipsen’s mission to discover, develop and deliver innovative medicines that help patients to prevail over serious diseases
We seek to be transparent about our actions while respecting legitimate intellectual property rights and data privacy
We take our commitments seriously and feel accountable for our actions and interactions
Transparency & Trust
Transparency and trust
Promoting the needs and rights of patients, employees and society at large is vital to us at Ipsen and it is exactly the objective and essence of our Corporate Social Responsibility Strategy. Our vision is to harness the power of our employees to have a responsible and sustainable impact on patients, society and the environment. We need to act with integrity, meaning that we must build relationships based on trust.
Transparency & Trust
In the USA, commercial interactions with HCPs are governed by the PhRMA Code on Interactions with Healthcare Professionals (2008). From a transparency perspective, the Patient Protection and Affordable Care Act (2010) (“Sunshine Act”) requires manufacturers to collect and track all financial relationships with physicians and teaching hospitals and to report this data to the Centers for Medicare and Medicaid Services (CMS).
The disclosures include transfers of value made for activities such as research and educational grants to HCOs as well as transfers of value to HCPs such as speaker fees, consultancy activities and participation in advisory boards.
Increasing transparency through the individual disclosure of transfers of value is good for all stakeholders, including HCPs, because it increases understanding of this important collaboration.
A customized training programme
As the cornerstone of our prevention program, awareness campaigns and training on environment, health and safety are regularly conducted. Each site has defined its training program according to its own risks and impacts. All employees are trained to recognize the inherent risks associated with their workplace and the environmental impact of their activities. These training programs meet our three commitments, formalized in the EHS Code of Conduct 3S:
Get personally involved
In your own safety and that of your colleagues and in the preservation of the environment. Consistently choose the safest way.
Share your ideas and concerns
Regarding the environment, health and safety. Have the courage to discuss risk situations openly with others, even when they are beyond your scope of responsibility.
Look for ways to continuously improve
Our EHS performance. Report every “good catch” and “dangerous situations” so we can prevent future injury or environmental damage
Clinical trials and data sharing
Pharmaceutical companies are committed to enhancing public health through responsible sharing of clinical trial data in a manner that is consistent with the following principles: Safeguarding the privacy of patients Respecting the integrity of national regulatory systems Maintaining incentives for investment in biomedical research.
Support to patient organizations
Patients are our best teachers and working with Patient organizations is essential to have a deep understanding of what matters most. We are open and transparent about the initiatives we support, the partnerships we’ve made and the Patient organizations with which we collaborate. These collaborations help us understand how we can best provide support along every step of the way. Based on our dedication to transparency and under the EFPIA Patient Organizations Code, Ipsen makes publicly available a list of patient organizations to which we provide financial support (grants, sponsorships, donations, etc. etc..) or significant non-financial support.
Environment, Health & Safety
We are committed to fostering a culture of continuous improvement to maintain the highest environment, health and safety (EHS) standards and to stand out as a world-class partner and employer of choice. We strive to integrate EHS excellence into our culture as we enable employees to deliver innovative products for patients worldwide. This starts with our S3 policy that helps us empower employees to ‘Step Up, Speak Out and Stay Safe’. Applying an organized, methodical approach, we are able to promote awareness and dialogue at every level.
“Promoting the needs and rights of patients, employees and society at large is really important, and it is exactly the objective and essence of our Corporate Social Responsibility strategy: A human journey of shared commitments. Our vision is to harness the power of our employees to have a responsible and sustainable impact on patients, society and the environment.”
Executive Vice-President, Chief Ethics and Compliance Officer
Initiatives across the world
Ipsen invests in the wider global community focusing our efforts on patient associations and charitable work. Our commitment reflects our corporate social responsibility policy and we believe that our employees are our leading ambassadors.
Engaging with external scientific discovery
In collaboration with the American Association for the Advancement of Science, we launched the Bridging Biomedical Worlds conference series in 2014 to boost cooperation among researchers, clinicians and industry scientists. The fourth edition took place in February 2018 in Singapore and explored ‘Genome Editing, the Next Frontier’ and the program covered revolutionary genome editing tools in various scientific fields, especially with respect to innovative therapies for cancer.
In a second event, developed in collaboration with the Karolinksa Institute, we examined how entrepreneurs can better serve patients through scientific innovation. This event in March 2018 was open to the public and engaged politicians, leading scientists and the business community.